Supplementary Table 1. Changes in PROs in Asian patients receiving sofosbuvir with and without interferon or ribavirin.
IFN ± RBV-containingN=90 / IFN-free RBV-free
N=15 / p
Treatment week 4
SF-36: physical functioning / -4.54 ± 28.05 / 3.08 ± 12.0 / 0.28
SF-36: role physical / -13.43 ± 23.00 & / 2.40 ± 15.84 / 0.0163
SF-36: bodily pain / -5.41 ± 23.43 / 6.31 ± 14.87 / 0.0347
SF-36: general health / -4.50 ± 16.73 / 5.23 ± 4.88 & / 0.0083
SF-36: vitality / -8.03 ± 22.47 & / 0.52 ± 15.64 / 0.08
SF-36: social functioning / -11.22 ± 19.64 & / 0.96 ± 20.70 / 0.08
SF-36: role emotional / -9.78 ± 19.90 & / 2.56 ± 22.66 / 0.09
SF-36: mental health / -5.47 ± 14.18 & / 7.08 ± 16.58 / 0.0112
SF-36: physical summary / -2.25 ± 7.95 / 1.02 ± 3.87 / 0.13
SF-36: mental summary / -4.34 ± 8.45 & / 2.67 ± 8.00 / 0.0071
FACIT-F: physical / -2.57 ± 5.21 & / -0.71 ± 1.92 / 0.26
FACIT-F: emotional / 0.22 ± 3.55 / 1.18 ± 2.98 / 0.19
FACIT-F: social / -1.50 ± 5.86 / 1.61 ± 4.05 / 0.0373
FACIT-F: functional / -1.71 ± 6.11 / 0.54 ± 4.24 / 0.14
FACIT-F: fatigue / -5.09 ± 11.96 & / -1.54 ± 4.99 / 0.25
FACIT-F: total / -10.54 ± 24.84 & / 1.09 ± 7.60 / 0.0331
CLDQ-HCV: activity / -0.54 ± 1.22 & / -0.08 ± 0.58 / 0.17
CLDQ-HCV: emotional / -0.26 ± 0.83 & / 0.20 ± 0.38 / 0.0173
CLDQ-HCV: worry / 0.12 ± 0.88 / 0.73 ± 0.76 & / 0.0159
CLDQ-HCV: systemic / -0.37 ± 1.07 & / 0.14 ± 0.82 / 0.13
CLDQ-HCV: total / -0.26 ± 0.84 & / 0.25 ± 0.48 / 0.0148
WPAI: work productivity / 0.196 ± 0.293 & / 0.017 ± 0.041 / 0.24
WPAI: absenteeism / 0.118 ± 0.269 & / 0.000 ± 0.000 / 0.28
WPAI: presenteeism / 0.087 ± 0.200 / 0.017 ± 0.041 / 0.60
WPAI: activity / 0.111 ± 0.297 & / 0.015 ± 0.134 / 0.0447
Utility: SF-6D / -0.025 ± 0.125 / 0.086 ± 0.164 / 0.0086
The last day of treatment
SF-36: physical functioning / -6.74 ± 27.09 & / 3.00 ± 14.37 / 0.12
SF-36: role physical / -13.50 ± 28.29 & / -0.42 ± 18.67 / 0.06
SF-36: bodily pain / -7.82 ± 29.14 & / 7.33 ± 22.57 / 0.10
SF-36: general health / -4.45 ± 17.05 & / 9.00 ± 14.49 & / 0.0018
SF-36: vitality / -9.04 ± 22.00 & / -3.75 ± 19.37 / 0.23
SF-36: social functioning / -11.99 ± 28.85 & / -1.67 ± 24.94 / 0.17
SF-36: role emotional / -13.50 ± 26.66 & / -1.67 ± 20.22 / 0.09
SF-36: mental health / -9.43 ± 19.62 & / 1.75 ± 21.41 / 0.10
SF-36: physical summary / -1.74 ± 7.69 / 2.34 ± 5.45 / 0.08
SF-36: mental summary / -5.77 ± 10.29 & / -0.99 ± 9.28 / 0.08
FACIT-F: physical / -2.43 ± 6.43 & / -0.48 ± 4.67 / 0.24
FACIT-F: emotional / 0.41 ± 4.32 / 1.33 ± 2.92 / 0.19
FACIT-F: social / -1.15 ± 6.13 / 2.13 ± 3.76 / 0.0315
FACIT-F: functional / -2.32 ± 4.78 & / -0.96 ± 3.27 / 0.30
FACIT-F: fatigue / -4.95 ± 12.43 & / 0.07 ± 8.92 / 0.07
FACIT-F: total / -9.68 ± 26.34 / 2.09 ± 14.49 / 0.11
CLDQ-HCV: activity / -0.48 ± 1.45 / -0.10 ± 0.93 / 0.41
CLDQ-HCV: emotional / -0.29 ± 1.11 / 0.18 ± 0.72 / 0.06
CLDQ-HCV: worry / 0.14 ± 1.04 / 0.57 ± 0.75 & / 0.12
CLDQ-HCV: systemic / -0.18 ± 1.07 / 0.24 ± 1.09 / 0.30
CLDQ-HCV: total / -0.20 ± 1.03 / 0.22 ± 0.71 / 0.16
WPAI: work productivity / 0.131 ± 0.298 / -0.018 ± 0.062 / 0.11
WPAI: absenteeism / 0.077 ± 0.191 & / 0.011 ± 0.028 / 0.46
WPAI: presenteeism / 0.046 ± 0.187 / -0.029 ± 0.049 / 0.12
WPAI: activity / 0.080 ± 0.299 & / 0.053 ± 0.226 / 0.45
Utility: SF-6D / -0.050 ± 0.164 & / 0.016 ± 0.177 / 0.24
Post-treatment week 4
SF-36: physical functioning / -0.54 ± 28.17 / 5.67 ± 12.08 / 0.25
SF-36: role physical / -7.40 ± 24.16 & / 7.08 ± 12.69 / 0.0075
SF-36: bodily pain / -1.98 ± 24.33 / 7.40 ± 17.20 / 0.18
SF-36: general health / 0.67 ± 17.75 / 12.20 ± 13.63 & / 0.0089
SF-36: vitality / -1.84 ± 23.15 / 3.61 ± 12.73 / 0.42
SF-36: social functioning / -8.75 ± 24.60 & / 5.00 ± 15.53 / 0.0180
SF-36: role emotional / -9.18 ± 24.06 & / 7.22 ± 15.06 / 0.0093
SF-36: mental health / -4.62 ± 18.44 / 8.33 ± 17.89 / 0.07
SF-36: physical summary / 0.24 ± 8.39 / 2.71 ± 5.14 / 0.17
SF-36: mental summary / -3.83 ± 9.59 & / 3.24 ± 7.48 / 0.0217
FACIT-F: physical / -1.23 ± 5.44 / 0.89 ± 2.70 / 0.11
FACIT-F: emotional / 0.75 ± 4.57 / 1.40 ± 3.07 / 0.29
FACIT-F: social / -0.61 ± 6.09 / 0.96 ± 4.56 / 0.29
FACIT-F: functional / -1.66 ± 4.92 / -0.64 ± 5.96 / 0.26
FACIT-F: fatigue / -2.52 ± 11.40 / 3.07 ± 7.20 / 0.06
FACIT-F: total / -4.80 ± 25.47 / 5.67 ± 16.36 / 0.12
CLDQ-HCV: activity / -0.28 ± 1.34 / 0.29 ± 0.67 / 0.11
CLDQ-HCV: emotional / -0.10 ± 1.04 / 0.30 ± 0.39 & / 0.10
CLDQ-HCV: worry / 0.12 ± 1.12 / 0.65 ± 0.68 & / 0.05
CLDQ-HCV: systemic / -0.14 ± 1.02 / 0.29 ± 0.90 / 0.15
CLDQ-HCV: total / -0.10 ± 0.97 / 0.38 ± 0.44 & / 0.0301
WPAI: work productivity / 0.066 ± 0.183 / 0.000 ± 0.058 / 0.39
WPAI: absenteeism / 0.026 ± 0.072 / 0.000 ± 0.000 / 0.39
WPAI: presenteeism / 0.043 ± 0.157 / 0.000 ± 0.058 / 0.71
WPAI: activity / 0.051 ± 0.258 & / 0.020 ± 0.190 / 0.37
Utility: SF-6D / -0.003 ± 0.147 / 0.106 ± 0.121 & / 0.0117
SVR-12
SF-36: physical functioning / 3.66 ± 25.32 / 6.33 ± 12.60 / 0.37
SF-36: role physical / -3.98 ± 24.19 / 0.83 ± 13.95 / 0.26
SF-36: bodily pain / 4.51 ± 22.96 / 13.00 ± 21.12 / 0.26
SF-36: general health / -1.23 ± 16.98 / 6.00 ± 17.56 / 0.15
SF-36: vitality / 2.27 ± 23.79 / 4.17 ± 17.94 / 0.90
SF-36: social functioning / -0.93 ± 27.46 / 5.83 ± 21.06 / 0.24
SF-36: role emotional / -2.83 ± 27.90 / 3.33 ± 18.31 / 0.37
SF-36: mental health / -1.14 ± 17.12 / 6.67 ± 16.55 / 0.25
SF-36: physical summary / 0.77 ± 7.30 / 2.52 ± 4.96 / 0.27
SF-36: mental summary / -1.21 ± 10.29 / 2.39 ± 6.79 / 0.18
FACIT-F: physical / -0.58 ± 4.86 / 0.56 ± 2.65 / 0.29
FACIT-F: emotional / 1.52 ± 4.06 & / 1.27 ± 2.37 / 0.88
FACIT-F: social / -1.37 ± 6.50 / -0.62 ± 8.15 / 0.34
FACIT-F: functional / -0.55 ± 3.75 / -0.48 ± 3.07 / 0.89
FACIT-F: fatigue / 1.03 ± 9.13 / 0.67 ± 5.29 / 0.78
FACIT-F: total / 2.18 ± 18.46 / 1.39 ± 11.04 / 0.97
CLDQ-HCV: activity / 0.13 ± 1.19 / 0.18 ± 0.62 / 0.95
CLDQ-HCV: emotional / 0.20 ± 1.03 / 0.20 ± 0.59 / 0.62
CLDQ-HCV: worry / 0.53 ± 1.16 & / 0.63 ± 0.70 & / 0.73
CLDQ-HCV: systemic / 0.04 ± 1.05 / 0.56 ± 0.96 & / 0.16
CLDQ-HCV: total / 0.23 ± 0.98 / 0.39 ± 0.56 & / 0.44
WPAI: work productivity / -0.058 ± 0.229 / 0.029 ± 0.046 / 0.19
WPAI: absenteeism / -0.002 ± 0.033 / 0.013 ± 0.031 / 0.41
WPAI: presenteeism / -0.056 ± 0.218 / 0.017 ± 0.041 / 0.15
WPAI: activity / -0.032 ± 0.257 / 0.131 ± 0.390 / 0.52
Utility: SF-6D / -0.001 ± 0.164 / 0.102 ± 0.167 / 0.06
& - p<0.05 when compared to no change (sign rank test)
Supplementary Table 2. Independent predictors of PROs in Asian patients with chronic hepatitis C before, during and after treatment.
PRO / Predictor / Beta / Std.Err. / pSF-36: PCS - baseline / Anxiety / 9.41 / 3.91 / 0.0181
Depression / -6.42 / 2.57 / 0.0144
Type 2 diabetes / -5.63 / 2.28 / 0.0153
Baseline hemoglobin, per 1 g/dL / 1.17 / 0.52 / 0.0270
SF-36: PCS – end of treatment / The use of LDV/SOF / 7.21 / 2.45 / 0.0041
Type 2 diabetes / -5.49 / 2.45 / 0.0274
SF-36: PCS – post- treatment week 4 / The use of LDV/SOF / 8.06 / 2.41 / 0.0013
Age, per year / -0.25 / 0.09 / 0.0050
Cirrhosis / 5.44 / 2.51 / 0.0334
SF-36: PCS – SVR-12 / The use of LDV/SOF / 6.53 / 2.17 / 0.0036
Age, per year / -0.28 / 0.08 / 0.0006
SF-36: MCS - baseline / Treatment-naïve / -7.54 / 2.01 / 0.0003
BMI, per 1.0 / 0.48 / 0.23 / 0.0377
Depression / -8.35 / 2.91 / 0.0051
Type 2 diabetes / -7.22 / 2.69 / 0.0088
SF-36: MCS – end of treatment / Type 2 diabetes / -7.81 / 3.17 / 0.0156
SF-36: MCS – post- treatment week 4 / SVR-12 / 8.77 / 3.61 / 0.0176
BMI, per 1.0 / 0.78 / 0.29 / 0.0094
Depression / -10.31 / 3.54 / 0.0047
Type 2 diabetes / -9.35 / 3.15 / 0.0040
SF-36: MCS – SVR-12 / Depression / -10.70 / 4.39 / 0.0174
FACIT-F: fatigue – baseline / Depression / -12.33 / 3.98 / 0.0030
Clinically overt fatigue / -14.64 / 7.14 / 0.0447
FACIT-F: fatigue – end of treatment / Type 2 diabetes / -11.39 / 4.51 / 0.0138
FACIT-F: fatigue – post-treatment week 4 / Type 2 diabetes / -11.95 / 3.43 / 0.0009
FACIT-F: fatigue – SVR-12 / No predictors
FACIT-F: total - baseline / Anxiety / 29.39 / 11.70 / 0.0148
Depression / -36.68 / 8.43 / 0.0001
Clinically overt fatigue / -50.32 / 16.08 / 0.0028
HCV RNA > 6 log 10 IU/mL / 14.73 / 6.32 / 0.0233
FACIT-F: total - end of treatment / The use of LDV/SOF / 24.05 / 8.37 / 0.0055
Type 2 diabetes / -24.98 / 10.29 / 0.0180
Cirrhosis / 25.76 / 9.20 / 0.0068
FACIT-F: total - post-treatment week 4 / Type 2 diabetes / -32.80 / 9.18 / 0.0007
FACIT-F: total - SVR-12 / Depression / -26.02 / 11.75 / 0.0307
CLDQ-HCV: total – baseline / Depression / -1.24 / 0.40 / 0.0030
Clinically overt fatigue / -1.48 / 0.73 / 0.0456
HCV > 6 log 10 / 0.69 / 0.29 / 0.0205
CLDQ-HCV: total – end of treatment / Treatment-naïve / 0.58 / 0.29 / 0.0449
Type 2 diabetes / -0.89 / 0.40 / 0.0308
Cirrhosis / 1.14 / 0.36 / 0.0023
CLDQ-HCV: total – post-treatment week 4 / Depression / -1.00 / 0.47 / 0.0374
Type 2 diabetes / -1.07 / 0.36 / 0.0042
CLDQ-HCV: total – SVR-12 / Age, per year / -0.02 / 0.01 / 0.0463
Depression / -1.06 / 0.46 / 0.0239
WPAI:SHP: Work productivity – baseline / Depression / 0.33 / 0.10 / 0.0019
WPAI:SHP: Work productivity – end of treatment / The use of LDV/SOF / -0.29 / 0.13 / 0.0268
WPAI:SHP: Work productivity – post-treatment week 4 / No predictors
WPAI:SHP: Work productivity – SVR-12 / BMI, per 1.0 / -0.03 / 0.01 / 0.0066
Type 2 diabetes / 0.30 / 0.12 / 0.0195
WPAI:SHP: Activity – baseline / No predictors
WPAI:SHP: Activity – end of treatment / No predictors
WPAI:SHP: Activity – post-treatment week 4 / BMI, per 1.0 / -0.01 / 0.01 / 0.0463
Type 2 diabetes / 0.25 / 0.08 / 0.0029
WPAI:SHP: Activity – SVR-12 / No predictors
Health utility: SF-6D – baseline / Depression / -0.14 / 0.05 / 0.0042
Health utility: SF-6D – end of treatment / Enrolled in the USA / 0.08 / 0.03 / 0.0172
Type 2 diabetes / -0.11 / 0.05 / 0.0184
Health utility: SF-6D – post-treatment week 4 / The use of LDV/SOF / 0.14 / 0.04 / 0.0012
Type 2 diabetes / -0.10 / 0.05 / 0.0353
Cirrhosis / 0.13 / 0.05 / 0.0063
Health utility: SF-6D – SVR-12 / The use of LDV/SOF / 0.14 / 0.04 / 0.0017
Supplementary Table 3. Independent predictors of PROs in patients with chronic hepatitis C. All betas are transformed to a 0-100% for a PRO. Reference treatment regime: RBV±IFN.
PRO: time point / Predictor / Beta / Std.Err. / pPCS: Baseline / Asian ethnicity / -7.73 / 2.51 / 0.0020
PCS: Baseline / Enrolled in the U.S. / 3.83 / 0.85 / 0.0000
PCS: Baseline / Age, per year / -0.24 / 0.04 / 0.0000
PCS: Baseline / BMI, per 1.0 / -0.79 / 0.08 / 0.0000
PCS: Baseline / Anxiety, history / -3.85 / 1.08 / 0.0004
PCS: Baseline / Depression, history / -8.64 / 0.90 / 0.0000
PCS: Baseline / Fatigue, history / -8.77 / 1.17 / 0.0000
PCS: Baseline / Insomnia, history / -5.78 / 1.00 / 0.0000
PCS: Baseline / Type 2 diabetes, history / -5.62 / 1.26 / 0.0000
PCS: Baseline / Cirrhosis / -4.39 / 1.00 / 0.0000
PCS: Baseline / ALT > 1.5 x ULN / 2.49 / 0.76 / 0.0011
PCS: Baseline / Hemoglobin, per 1 g/dL / 1.42 / 0.28 / 0.0000
PCS: End of treatment / Asian ethnicity / -10.56 / 2.61 / 0.0001
PCS: End of treatment / The use of LDV/SOF / 9.23 / 0.87 / 0.0000
PCS: End of treatment / Enrolled in the U.S. / 4.12 / 0.90 / 0.0000
PCS: End of treatment / Age, per year / -0.38 / 0.04 / 0.0000
PCS: End of treatment / Male gender / 3.24 / 0.81 / 0.0001
PCS: End of treatment / BMI, per 1.0 / -0.67 / 0.08 / 0.0000
PCS: End of treatment / Anxiety, history / -3.67 / 1.13 / 0.0012
PCS: End of treatment / Depression, history / -7.21 / 0.95 / 0.0000
PCS: End of treatment / Fatigue, history / -7.82 / 1.22 / 0.0000
PCS: End of treatment / Insomnia, history / -6.00 / 1.05 / 0.0000
PCS: End of treatment / Type 2 diabetes, history / -5.56 / 1.30 / 0.0000
PCS: End of treatment / Cirrhosis / -3.64 / 1.04 / 0.0005
PCS: post-treatment week 4 / Asian ethnicity / -8.23 / 2.72 / 0.0025
PCS: post-treatment week 4 / The use of LDV/SOF / 4.83 / 0.85 / 0.0000
PCS: post-treatment week 4 / Enrolled in the U.S. / 5.04 / 0.88 / 0.0000
PCS: post-treatment week 4 / Age, per year / -0.31 / 0.04 / 0.0000
PCS: post-treatment week 4 / Male gender / 3.31 / 0.80 / 0.0000
PCS: post-treatment week 4 / BMI, per 1.0 / -0.68 / 0.08 / 0.0000
PCS: post-treatment week 4 / Anxiety, history / -3.32 / 1.12 / 0.0031
PCS: post-treatment week 4 / Depression, history / -7.41 / 0.93 / 0.0000
PCS: post-treatment week 4 / Fatigue, history / -6.85 / 1.21 / 0.0000
PCS: post-treatment week 4 / Insomnia, history / -6.42 / 1.03 / 0.0000
PCS: post-treatment week 4 / Type 2 diabetes, history / -6.18 / 1.28 / 0.0000
PCS: post-treatment week 4 / Cirrhosis / -4.72 / 1.03 / 0.0000
PCS: SVR-12 / Asian ethnicity / -6.60 / 2.92 / 0.0240
PCS: SVR-12 / The use of LDV/SOF / 2.17 / 0.85 / 0.0109
PCS: SVR-12 / Enrolled in the U.S. / 4.91 / 0.93 / 0.0000
PCS: SVR-12 / Age, per year / -0.29 / 0.04 / 0.0000
PCS: SVR-12 / Caucasian race / 2.57 / 1.20 / 0.0324
PCS: SVR-12 / BMI, per 1.0 / -0.61 / 0.08 / 0.0000
PCS: SVR-12 / Anxiety, history / -4.70 / 1.15 / 0.0000
PCS: SVR-12 / Depression, history / -7.98 / 0.96 / 0.0000
PCS: SVR-12 / Fatigue, history / -6.23 / 1.27 / 0.0000
PCS: SVR-12 / Insomnia, history / -6.22 / 1.07 / 0.0000
PCS: SVR-12 / Type 2 diabetes, history / -6.16 / 1.34 / 0.0000
PCS: SVR-12 / Cirrhosis / -5.73 / 1.11 / 0.0000
MCS: Baseline / Enrolled in the U.S. / 11.74 / 0.70 / 0.0000
MCS: Baseline / Age, per year / 0.13 / 0.03 / 0.0001
MCS: Baseline / Male gender / 1.35 / 0.66 / 0.0414
MCS: Baseline / Anxiety, history / -6.94 / 0.91 / 0.0000
MCS: Baseline / Depression, history / -11.53 / 0.76 / 0.0000
MCS: Baseline / Fatigue, history / -5.48 / 0.99 / 0.0000
MCS: Baseline / Insomnia, history / -3.79 / 0.85 / 0.0000
MCS: Baseline / Type 2 diabetes, history / -2.56 / 1.05 / 0.0145
MCS: Baseline / Cirrhosis / -3.03 / 0.83 / 0.0003
MCS: Baseline / HCV > 6 log 10 IU/mL / 1.74 / 0.76 / 0.0215
MCS: End of treatment / The use of LDV/SOF / 9.08 / 0.79 / 0.0000
MCS: End of treatment / Enrolled in the U.S. / 11.52 / 0.79 / 0.0000
MCS: End of treatment / Anxiety, history / -8.53 / 1.03 / 0.0000
MCS: End of treatment / Depression, history / -11.24 / 0.87 / 0.0000
MCS: End of treatment / Fatigue, history / -4.88 / 1.12 / 0.0000
MCS: End of treatment / Insomnia, history / -2.40 / 0.96 / 0.0125
MCS: End of treatment / Cirrhosis / -1.96 / 0.93 / 0.0355
MCS: post-treatment week 4 / The use of LDV/SOF / 4.30 / 0.75 / 0.0000
MCS: post-treatment week 4 / Duration of the regimen, per week / -0.14 / 0.06 / 0.0170
MCS: post-treatment week 4 / Enrolled in the U.S. / 11.59 / 0.79 / 0.0000
MCS: post-treatment week 4 / Anxiety, history / -7.23 / 0.99 / 0.0000
MCS: post-treatment week 4 / Depression, history / -10.57 / 0.82 / 0.0000
MCS: post-treatment week 4 / Fatigue, history / -3.75 / 1.07 / 0.0005
MCS: post-treatment week 4 / Insomnia, history / -3.73 / 0.92 / 0.0000
MCS: post-treatment week 4 / Type 2 diabetes, history / -2.24 / 1.11 / 0.0447
MCS: SVR-12 / The use of LDV/SOF / 1.65 / 0.76 / 0.0292
MCS: SVR-12 / Duration of the regimen, per week / -0.14 / 0.06 / 0.0181
MCS: SVR-12 / Enrolled in the U.S. / 11.28 / 0.82 / 0.0000
MCS: SVR-12 / Anxiety, history / -8.18 / 1.02 / 0.0000
MCS: SVR-12 / Depression, history / -10.26 / 0.86 / 0.0000
MCS: SVR-12 / Fatigue, history / -3.27 / 1.13 / 0.0039
MCS: SVR-12 / Insomnia, history / -2.80 / 0.95 / 0.0033
MCS: SVR-12 / Cirrhosis / -2.89 / 0.98 / 0.0032
Fatigue: Baseline / Enrolled in the U.S. / 6.75 / 0.76 / 0.0000
Fatigue: Baseline / Male gender / 2.63 / 0.72 / 0.0002
Fatigue: Baseline / BMI, per 1.0 / -0.29 / 0.07 / 0.0000
Fatigue: Baseline / Anxiety, history / -4.71 / 0.99 / 0.0000
Fatigue: Baseline / Depression, history / -12.03 / 0.83 / 0.0000
Fatigue: Baseline / Fatigue, history / -13.21 / 1.09 / 0.0000
Fatigue: Baseline / Insomnia, history / -4.26 / 0.92 / 0.0000
Fatigue: Baseline / Type 2 diabetes, history / -3.57 / 1.14 / 0.0018
Fatigue: Baseline / Cirrhosis / -3.49 / 0.88 / 0.0001
Fatigue: End of treatment / Asian ethnicity / -8.37 / 2.93 / 0.0042
Fatigue: End of treatment / The use of LDV/SOF / 10.34 / 0.84 / 0.0000
Fatigue: End of treatment / Enrolled in the U.S. / 4.96 / 0.88 / 0.0000
Fatigue: End of treatment / Age, per year / -0.15 / 0.04 / 0.0001
Fatigue: End of treatment / Caucasian ethnicity / -4.60 / 1.15 / 0.0001
Fatigue: End of treatment / Male gender / 3.82 / 0.80 / 0.0000
Fatigue: End of treatment / Treatment-naive / 2.02 / 0.81 / 0.0128
Fatigue: End of treatment / BMI, per 1.0 / -0.31 / 0.08 / 0.0001
Fatigue: End of treatment / Anxiety, history / -5.59 / 1.12 / 0.0000
Fatigue: End of treatment / Depression, history / -9.74 / 0.93 / 0.0000
Fatigue: End of treatment / Fatigue, history / -8.10 / 1.21 / 0.0000
Fatigue: End of treatment / Insomnia, history / -3.60 / 1.03 / 0.0005
Fatigue: End of treatment / Type 2 diabetes, history / -4.31 / 1.28 / 0.0008
Fatigue: post-treatment week 4 / The use of LDV/SOF / 3.97 / 0.72 / 0.0000
Fatigue: post-treatment week 4 / Enrolled in the U.S. / 7.46 / 0.76 / 0.0000
Fatigue: post-treatment week 4 / Age, per year / -0.08 / 0.03 / 0.0211
Fatigue: post-treatment week 4 / Male gender / 1.36 / 0.69 / 0.0489
Fatigue: post-treatment week 4 / BMI, per 1.0 / -0.25 / 0.07 / 0.0002
Fatigue: post-treatment week 4 / Anxiety, history / -5.81 / 0.96 / 0.0000
Fatigue: post-treatment week 4 / Depression, history / -9.60 / 0.80 / 0.0000
Fatigue: post-treatment week 4 / Fatigue, history / -5.85 / 1.05 / 0.0000
Fatigue: post-treatment week 4 / Insomnia, history / -4.03 / 0.89 / 0.0000
Fatigue: post-treatment week 4 / Type 2 diabetes, history / -3.50 / 1.11 / 0.0016
Fatigue: post-treatment week 4 / Cirrhosis / -2.16 / 0.88 / 0.0144
Fatigue: SVR-12 / Enrolled in the U.S. / 6.34 / 0.73 / 0.0000
Fatigue: SVR-12 / Treatment-naive / 1.18 / 0.70 / 0.0901
Fatigue: SVR-12 / BMI, per 1.0 / -0.18 / 0.07 / 0.0062
Fatigue: SVR-12 / Anxiety, history / -4.97 / 0.93 / 0.0000
Fatigue: SVR-12 / Depression, history / -9.89 / 0.78 / 0.0000
Fatigue: SVR-12 / Fatigue, history / -6.56 / 1.03 / 0.0000
Fatigue: SVR-12 / Insomnia, history / -3.72 / 0.87 / 0.0000
Fatigue: SVR-12 / Type 2 diabetes, history / -3.35 / 1.08 / 0.0019
Fatigue: SVR-12 / Cirrhosis / -1.78 / 0.89 / 0.0459
Total FACIT-F: Baseline / Enrolled in the U.S. / 7.31 / 0.59 / 0.0000
Total FACIT-F: Baseline / BMI, per 1.0 / -0.18 / 0.05 / 0.0010
Total FACIT-F: Baseline / Anxiety, history / -4.55 / 0.76 / 0.0000
Total FACIT-F: Baseline / Depression, history / -9.48 / 0.63 / 0.0000
Total FACIT-F: Baseline / Fatigue, history / -7.77 / 0.83 / 0.0000
Total FACIT-F: Baseline / Insomnia, history / -4.04 / 0.70 / 0.0000
Total FACIT-F: Baseline / Type 2 diabetes, history / -3.61 / 0.87 / 0.0000
Total FACIT-F: Baseline / Cirrhosis / -2.75 / 0.67 / 0.0000
Total FACIT-F: Baseline / Hemoglobin, per 1 g/dL / 0.41 / 0.20 / 0.0355
Total FACIT-F: End of treatment / Asian ethnicity / -6.81 / 2.28 / 0.0029
Total FACIT-F: End of treatment / The use of LDV/SOF / 7.60 / 0.65 / 0.0000
Total FACIT-F: End of treatment / Enrolled in the U.S. / 6.65 / 0.69 / 0.0000
Total FACIT-F: End of treatment / Age, per year / -0.10 / 0.03 / 0.0008
Total FACIT-F: End of treatment / Caucasian ethnicity / -2.44 / 0.89 / 0.0060
Total FACIT-F: End of treatment / Male gender / 1.56 / 0.62 / 0.0110
Total FACIT-F: End of treatment / Treatment-naive / 1.26 / 0.64 / 0.0472
Total FACIT-F: End of treatment / BMI, per 1.0 / -0.17 / 0.06 / 0.0047
Total FACIT-F: End of treatment / Anxiety, history / -5.43 / 0.86 / 0.0000
Total FACIT-F: End of treatment / Depression, history / -8.20 / 0.72 / 0.0000
Total FACIT-F: End of treatment / Fatigue, history / -5.65 / 0.93 / 0.0000
Total FACIT-F: End of treatment / Insomnia, history / -2.97 / 0.80 / 0.0002
Total FACIT-F: End of treatment / Type 2 diabetes, history / -3.79 / 0.99 / 0.0001
Total FACIT-F: End of treatment / Cirrhosis / -1.60 / 0.80 / 0.0452
Total FACIT-F: post-treatment week 4 / The use of LDV/SOF / 3.61 / 0.59 / 0.0000
Total FACIT-F: post-treatment week 4 / Enrolled in the U.S. / 7.99 / 0.61 / 0.0000
Total FACIT-F: post-treatment week 4 / BMI, per 1.0 / -0.15 / 0.05 / 0.0073
Total FACIT-F: post-treatment week 4 / Anxiety, history / -5.43 / 0.79 / 0.0000
Total FACIT-F: post-treatment week 4 / Depression, history / -8.19 / 0.65 / 0.0000
Total FACIT-F: post-treatment week 4 / Fatigue, history / -4.07 / 0.86 / 0.0000
Total FACIT-F: post-treatment week 4 / Insomnia, history / -3.70 / 0.73 / 0.0000
Total FACIT-F: post-treatment week 4 / Type 2 diabetes, history / -3.74 / 0.90 / 0.0000
Total FACIT-F: post-treatment week 4 / Cirrhosis / -2.52 / 0.72 / 0.0004
Total FACIT-F: SVR-12 / The use of LDV/SOF / 1.34 / 0.58 / 0.0206
Total FACIT-F: SVR-12 / Enrolled in the U.S. / 7.42 / 0.61 / 0.0000
Total FACIT-F: SVR-12 / Anxiety, history / -5.16 / 0.79 / 0.0000
Total FACIT-F: SVR-12 / Depression, history / -7.96 / 0.66 / 0.0000
Total FACIT-F: SVR-12 / Fatigue, history / -3.88 / 0.87 / 0.0000
Total FACIT-F: SVR-12 / Insomnia, history / -3.76 / 0.73 / 0.0000
Total FACIT-F: SVR-12 / Type 2 diabetes, history / -3.67 / 0.90 / 0.0000
Total FACIT-F: SVR-12 / Cirrhosis / -3.25 / 0.75 / 0.0000
CLDQ-HCV: Baseline / Enrolled in the U.S. / 6.30 / 0.64 / 0.0000
CLDQ-HCV: Baseline / Male gender / 2.13 / 0.60 / 0.0004
CLDQ-HCV: Baseline / BMI, per 1.0 / -0.21 / 0.06 / 0.0003
CLDQ-HCV: Baseline / Anxiety, history / -5.39 / 0.83 / 0.0000
CLDQ-HCV: Baseline / Depression, history / -8.92 / 0.69 / 0.0000
CLDQ-HCV: Baseline / Fatigue, history / -7.34 / 0.91 / 0.0000
CLDQ-HCV: Baseline / Insomnia, history / -5.31 / 0.77 / 0.0000
CLDQ-HCV: Baseline / Type 2 diabetes, history / -3.72 / 0.95 / 0.0001
CLDQ-HCV: Baseline / Cirrhosis / -5.10 / 0.74 / 0.0000
CLDQ-HCV: End of treatment / The use of LDV/SOF / 7.75 / 0.66 / 0.0000
CLDQ-HCV: End of treatment / Enrolled in the U.S. / 6.77 / 0.69 / 0.0000
CLDQ-HCV: End of treatment / Age, per year / -0.11 / 0.03 / 0.0007
CLDQ-HCV: End of treatment / Male gender / 2.01 / 0.63 / 0.0015
CLDQ-HCV: End of treatment / Treatment-naive / 1.95 / 0.65 / 0.0030
CLDQ-HCV: End of treatment / BMI, per 1.0 / -0.20 / 0.06 / 0.0017
CLDQ-HCV: End of treatment / Anxiety, history / -6.45 / 0.88 / 0.0000
CLDQ-HCV: End of treatment / Depression, history / -7.08 / 0.73 / 0.0000
CLDQ-HCV: End of treatment / Fatigue, history / -4.99 / 0.95 / 0.0000
CLDQ-HCV: End of treatment / Insomnia, history / -3.51 / 0.81 / 0.0000
CLDQ-HCV: End of treatment / Type 2 diabetes, history / -3.03 / 1.00 / 0.0026
CLDQ-HCV: End of treatment / Cirrhosis / -3.31 / 0.82 / 0.0001
CLDQ-HCV: post-treatment week 4 / Asian ethnicity / -4.70 / 2.03 / 0.0207
CLDQ-HCV: post-treatment week 4 / The use of LDV/SOF / 3.61 / 0.62 / 0.0000
CLDQ-HCV: post-treatment week 4 / Enrolled in the U.S. / 7.51 / 0.65 / 0.0000
CLDQ-HCV: post-treatment week 4 / Age, per year / -0.09 / 0.03 / 0.0026
CLDQ-HCV: post-treatment week 4 / Treatment-naive / 1.70 / 0.61 / 0.0054
CLDQ-HCV: post-treatment week 4 / BMI, per 1.0 / -0.16 / 0.06 / 0.0052
CLDQ-HCV: post-treatment week 4 / Anxiety, history / -6.27 / 0.82 / 0.0000
CLDQ-HCV: post-treatment week 4 / Depression, history / -6.74 / 0.68 / 0.0000
CLDQ-HCV: post-treatment week 4 / Fatigue, history / -3.77 / 0.89 / 0.0000
CLDQ-HCV: post-treatment week 4 / Insomnia, history / -4.16 / 0.76 / 0.0000
CLDQ-HCV: post-treatment week 4 / Type 2 diabetes, history / -2.86 / 0.94 / 0.0025
CLDQ-HCV: post-treatment week 4 / Cirrhosis / -3.66 / 0.77 / 0.0000
CLDQ-HCV: SVR-12 / The use of LDV/SOF / 1.29 / 0.61 / 0.0330
CLDQ-HCV: SVR-12 / Enrolled in the U.S. / 6.94 / 0.64 / 0.0000
CLDQ-HCV: SVR-12 / Age, per year / -0.09 / 0.03 / 0.0031
CLDQ-HCV: SVR-12 / Treatment-naive / 1.48 / 0.62 / 0.0169
CLDQ-HCV: SVR-12 / Anxiety, history / -6.17 / 0.82 / 0.0000
CLDQ-HCV: SVR-12 / Depression, history / -6.97 / 0.68 / 0.0000
CLDQ-HCV: SVR-12 / Fatigue, history / -4.06 / 0.91 / 0.0000
CLDQ-HCV: SVR-12 / Insomnia, history / -4.07 / 0.76 / 0.0000
CLDQ-HCV: SVR-12 / Type 2 diabetes, history / -3.79 / 0.94 / 0.0001
CLDQ-HCV: SVR-12 / Cirrhosis / -4.27 / 0.81 / 0.0000
Work productivity: Baseline / Enrolled in the U.S. / 2.85 / 1.02 / 0.0052
Work productivity: Baseline / Anxiety, history / -3.05 / 1.35 / 0.0240
Work productivity: Baseline / Depression, history / -4.29 / 1.16 / 0.0002
Work productivity: Baseline / Fatigue, history / -10.95 / 1.44 / 0.0000
Work productivity: Baseline / Cirrhosis / -5.26 / 1.22 / 0.0000
Work productivity: End of treatment / Asian ethnicity / -9.99 / 4.37 / 0.0224
Work productivity: End of treatment / The use of LDV/SOF / 13.31 / 1.31 / 0.0000
Work productivity: End of treatment / Duration of treatment, per week / 0.21 / 0.11 / 0.0420
Work productivity: End of treatment / Enrolled in the U.S. / 3.83 / 1.46 / 0.0089
Work productivity: End of treatment / Male gender / 3.25 / 1.28 / 0.0113
Work productivity: End of treatment / Depression, history / -6.11 / 1.54 / 0.0001
Work productivity: End of treatment / Fatigue, history / -7.68 / 1.90 / 0.0001
Work productivity: post-treatment week 4 / Asian ethnicity / -9.02 / 3.36 / 0.0074
Work productivity: post-treatment week 4 / The use of LDV/SOF / 4.43 / 1.01 / 0.0000
Work productivity: post-treatment week 4 / Enrolled in the U.S. / 5.25 / 1.09 / 0.0000
Work productivity: post-treatment week 4 / Depression, history / -4.94 / 1.20 / 0.0000
Work productivity: post-treatment week 4 / Fatigue, history / -4.37 / 1.50 / 0.0037
Work productivity: post-treatment week 4 / Insomnia, history / -2.76 / 1.32 / 0.0362
Work productivity: SVR-12 / Asian ethnicity / -9.26 / 3.26 / 0.0046
Work productivity: SVR-12 / Enrolled in the U.S. / 4.93 / 0.98 / 0.0000
Work productivity: SVR-12 / Treatment-naive / 2.06 / 0.91 / 0.0242
Work productivity: SVR-12 / Depression, history / -2.84 / 1.09 / 0.0095
Work productivity: SVR-12 / Fatigue, history / -2.80 / 1.36 / 0.0398
Work productivity: SVR-12 / Insomnia, history / -3.46 / 1.20 / 0.0039
Work productivity: SVR-12 / Cirrhosis / -4.43 / 1.27 / 0.0005
Activity: Baseline / Enrolled in the U.S. / 6.95 / 0.91 / 0.0000
Activity: Baseline / Male gender / 3.36 / 0.84 / 0.0001
Activity: Baseline / BMI, per 1.0 / -0.24 / 0.08 / 0.0035
Activity: Baseline / Anxiety, history / -4.58 / 1.16 / 0.0001
Activity: Baseline / Depression, history / -9.45 / 0.97 / 0.0000
Activity: Baseline / Fatigue, history / -14.45 / 1.27 / 0.0000
Activity: Baseline / Insomnia, history / -3.72 / 1.08 / 0.0006
Activity: Baseline / Type 2 diabetes, history / -4.18 / 1.33 / 0.0017
Activity: Baseline / Cirrhosis / -8.51 / 1.04 / 0.0000
Activity: End of treatment / Asian ethnicity / -6.89 / 3.25 / 0.0341
Activity: End of treatment / The use of LDV/SOF / 11.69 / 0.97 / 0.0000
Activity: End of treatment / Duration of treatment, per week / 0.19 / 0.08 / 0.0153
Activity: End of treatment / Enrolled in the U.S. / 6.36 / 1.06 / 0.0000
Activity: End of treatment / Age, per year / -0.23 / 0.05 / 0.0000
Activity: End of treatment / Male gender / 3.94 / 0.94 / 0.0000
Activity: End of treatment / Anxiety, history / -4.60 / 1.29 / 0.0004
Activity: End of treatment / Depression, history / -8.63 / 1.08 / 0.0000
Activity: End of treatment / Fatigue, history / -6.66 / 1.40 / 0.0000
Activity: End of treatment / Cirrhosis / -5.47 / 1.19 / 0.0000
Activity: post-treatment week 4 / The use of LDV/SOF / 3.93 / 0.84 / 0.0000
Activity: post-treatment week 4 / Enrolled in the U.S. / 9.13 / 0.89 / 0.0000
Activity: post-treatment week 4 / Age, per year / -0.11 / 0.04 / 0.0067
Activity: post-treatment week 4 / Caucasian ethnicity / 3.40 / 1.09 / 0.0018
Activity: post-treatment week 4 / Male gender / 2.18 / 0.81 / 0.0071
Activity: post-treatment week 4 / Treatment-naive / 2.55 / 0.84 / 0.0024
Activity: post-treatment week 4 / Anxiety, history / -5.06 / 1.12 / 0.0000
Activity: post-treatment week 4 / Depression, history / -7.54 / 0.94 / 0.0000
Activity: post-treatment week 4 / Fatigue, history / -5.04 / 1.22 / 0.0000
Activity: post-treatment week 4 / Insomnia, history / -3.06 / 1.04 / 0.0034
Activity: post-treatment week 4 / Type 2 diabetes, history / -2.70 / 1.29 / 0.0360
Activity: post-treatment week 4 / Cirrhosis / -5.69 / 1.06 / 0.0000
Activity: SVR-12 / Enrolled in the U.S. / 8.41 / 0.82 / 0.0000
Activity: SVR-12 / Age, per year / -0.09 / 0.04 / 0.0108
Activity: SVR-12 / Caucasian ethnicity / 3.57 / 1.04 / 0.0006
Activity: SVR-12 / Anxiety, history / -5.07 / 1.05 / 0.0000
Activity: SVR-12 / Depression, history / -5.25 / 0.88 / 0.0000
Activity: SVR-12 / Fatigue, history / -4.54 / 1.16 / 0.0001
Activity: SVR-12 / Insomnia, history / -3.34 / 0.98 / 0.0006
Activity: SVR-12 / Type 2 diabetes, history / -3.14 / 1.22 / 0.0102
Activity: SVR-12 / Cirrhosis / -7.56 / 0.99 / 0.0000
SF-6D: Baseline / Enrolled in the U.S. / 6.16 / 0.63 / <0.0001
SF-6D: Baseline / BMI, per 1.0 / -0.22 / 0.06 / 0.0001
SF-6D: Baseline / Anxiety, history / -4.57 / 0.79 / <0.0001
SF-6D: Baseline / Depression, history / -9.15 / 0.67 / <0.0001
SF-6D: Baseline / Fatigue, history / -6.01 / 0.86 / <0.0001
SF-6D: Baseline / Insomnia, history / -4.29 / 0.74 / <0.0001
SF-6D: Baseline / Type 2 diabetes, history / -3.47 / 0.93 / 0.0002
SF-6D: Baseline / Cirrhosis / -2.76 / 0.73 / 0.0002
SF-6D: Baseline / Hemoglobin, per 1 g/dL / 0.53 / 0.21 / 0.0103
SF-6D: End of treatment / Asian ethnicity / -7.61 / 2.19 / 0.0005
SF-6D: End of treatment / The use of LDV/SOF / 9.27 / 0.68 / <0.0001
SF-6D: End of treatment / Enrolled in the U.S. / 6.10 / 0.71 / <0.0001
SF-6D: End of treatment / Age, per year / -0.23 / 0.03 / <0.0001
SF-6D: End of treatment / Caucasian ethnicity / -2.54 / 0.92 / 0.0057
SF-6D: End of treatment / Male gender / 2.07 / 0.63 / 0.0010
SF-6D: End of treatment / BMI, per 1.0 / -0.22 / 0.06 / 0.0002
SF-6D: End of treatment / Anxiety, history / -5.74 / 0.87 / <0.0001
SF-6D: End of treatment / Depression, history / -8.34 / 0.73 / <0.0001
SF-6D: End of treatment / Fatigue, history / -4.92 / 0.94 / <0.0001
SF-6D: End of treatment / Insomnia, history / -3.45 / 0.81 / <0.0001
SF-6D: End of treatment / Type 2 diabetes, history / -2.86 / 1.00 / 0.0045
SF-6D: post-treatment week 4 / The use of LDV/SOF / 5.20 / 0.69 / <0.0001
SF-6D: post-treatment week 4 / Enrolled in the U.S. / 7.96 / 0.72 / <0.0001
SF-6D: post-treatment week 4 / Age, per year / -0.18 / 0.03 / <0.0001
SF-6D: post-treatment week 4 / Male gender / 1.82 / 0.64 / 0.0048
SF-6D: post-treatment week 4 / BMI, per 1.0 / -0.24 / 0.06 / 0.0001
SF-6D: post-treatment week 4 / Anxiety, history / -5.25 / 0.90 / <0.0001
SF-6D: post-treatment week 4 / Depression, history / -8.14 / 0.75 / <0.0001
SF-6D: post-treatment week 4 / Fatigue, history / -4.38 / 0.96 / <0.0001
SF-6D: post-treatment week 4 / Insomnia, history / -4.25 / 0.83 / <0.0001
SF-6D: post-treatment week 4 / Type 2 diabetes, history / -3.17 / 1.03 / 0.0022
SF-6D: post-treatment week 4 / Cirrhosis / -2.43 / 0.83 / 0.0036
SF-6D: SVR-12 / The use of LDV/SOF / 3.33 / 0.72 / <0.0001
SF-6D: SVR-12 / Duration of treatment, per week / -0.13 / 0.06 / 0.0171
SF-6D: SVR-12 / Enrolled in the U.S. / 8.20 / 0.81 / <0.0001
SF-6D: SVR-12 / Age, per year / -0.18 / 0.03 / <0.0001
SF-6D: SVR-12 / BMI, per 1.0 / -0.21 / 0.07 / 0.0015
SF-6D: SVR-12 / Anxiety, history / -6.32 / 0.96 / <0.0001
SF-6D: SVR-12 / Depression, history / -8.99 / 0.81 / <0.0001
SF-6D: SVR-12 / Fatigue, history / -4.63 / 1.06 / <0.0001
SF-6D: SVR-12 / Insomnia, history / -4.98 / 0.90 / <0.0001
SF-6D: SVR-12 / Type 2 diabetes, history / -2.85 / 1.12 / 0.0111
SF-6D: SVR-12 / Cirrhosis / -3.04 / 0.95 / 0.0014
Supplementary Figure 1. Changes in PROs in Asian vs. non-Asian patients: treatment week 4. (A) RBV±IFN-based treatment; (B) IFN-free RBV-free LDV/SOF.